A $1 billion fund backed by over 20 drugmakers made its first set of investments on April 4 in two biotechnology startups, nearly two years after it was launched to help struggling antibiotic makers tackle the threat of antibiotic-resistant bacteria.

Atlas Venture successfully raised $450 million at the close of the venture capital firm’s thirteenth fundraising activity to support efforts to create and invest in new biotech firms that address many unmet patient needs. 

Hal Barron, who guided the reinvigoration of the pharmaceutical direction at GlaxoSmithKline, is departing the company as GSK undergoes a planned demerger later during 2022.

BioSpace presented its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.

Isomorphic Laboratories, an AI-driven startup owned by Google parent firm Alphabet, announced plans to foray into drug discovery and development by tapping into the technology of its sister company DeepMind. 

Seattle-based AltPep Corporation raised $23.15 million in a Series A financing round to take the company’s breakthrough amyloid targeting platform to development.

Rebecca Vaught never set out to become an entrepreneur, but that’s exactly what happened when she launched Van Heron Labs during 2020 with a goal of reframing the understanding of the body’s organismal and cellular performance.

The Renopharma saga for GlaxoSmithKline is one step closer to being settled in court. A Chinese scientist living abroad who has been accused of accepting stolen intellectual property to benefit a pharma startup in China has been extradited to the United States.

Klick Health’s growing commercialization partner portfolio is proud of the successful exit of Circulation, one of Klick’s first incubation initiatives.

Two former executives of Sanofi and Merrimack Pharmaceuticals launched Partner Therapeutics (PTx) to focus on oncology.